For research use only. Not for human consumption, diagnostic, or therapeutic use.

Adding Private Label BPC-157 to Your Product Line – Introduction and Definition

BPC-157 generates 165,000 monthly U.S. searches according to industry keyword research data as of January 2026. Despite that demand, most entrepreneurs lack a clear path to private labeling it. This article explains how to add BPC-157 to your product line – from purity testing and COAs to compliant labeling and white-label dropshipping.

Entrepreneurs and clinic owners building their own RUO research peptide brand need a reliable supplier. YourPeptideBrand offers a turnkey solution with no minimum order quantities, custom labels, and direct dropship.

YourPeptideBrand defines BPC-157 (Body Protection Compound-157) as a synthetic pentadecapeptide of 15 amino acids (CAS: 137525-51-0, molecular weight 1,419.5 Da) derived from a protective protein naturally present in human gastric juice. It is classified as Research Use Only and is one of the most studied research peptides in the world.

First discovered by Sikiric et al. at the University of Zagreb in the early 1990s – the first PubMed entry dates to 1992 – BPC-157 is stable in gastric acid. Its 15-amino-acid sequence gives it unique structural properties that distinguish it from other research peptides. The complete sequence and helical conformation have been characterized in multiple studies, making it a frequent subject of in vivo and in vitro investigations.

For those planning to add BPC-157 to their product line, understanding what the compound is and how it is sourced matters. BPC-157 Complete Research Guide provides further details on the molecule’s history and research applications.

Mechanism of Action and Published Research on BPC-157

BPC-157 does not bind to a single known receptor. Its effects in research models come from a polypharmacological profile that engages multiple signaling pathways. Studies suggest activation of VEGFR2 drives angiogenesis, while the FAK-paxillin pathway triggers fibroblast migration and tendon cell outgrowth. The compound also modulates the nitric oxide system – upregulating eNOS and dampening iNOS – and elevates GH receptor expression. Seiwerth et al. (2018) provided a comprehensive overview of these mechanisms in Current Pharmaceutical Design (PMC6271067). A 2025 narrative review by Jozwiak et al. in Pharmaceuticals reaffirmed the compound’s unusual, multi-pathway activity in preclinical models (PMID 40005999).

Published research on BPC-157 has accelerated sharply. PubMed indexed roughly 45 publications in 2020; by 2025 that count exceeded 180 – a 4x increase in five years. A 2025 systematic review by Vasireddi et al. screened 544 articles from 1993 to 2024 and found consistently improved outcomes across tendon, ligament, muscle, and bone preclinical models (PMID 40756949). Gwyer et al. (2019) concluded that all studies they reviewed showed positive regenerative effects across multiple soft tissue types (PMID 30915550). Human safety data is emerging: four published investigations reported zero adverse events among research subjects, including a Phase II study for ulcerative colitis (Lee & Burgess 2025, PMID 40131143).

The White-Label Opportunity and Quality Requirements for Private Label BPC-157

White-Label Opportunity

BPC-157 generates roughly 165,000 monthly US searches, making it the highest-demand research peptide outside the weight-loss category. Its keyword difficulty sits between KD 4 and 8, a fraction of the KD 20-35 that dominates weight-loss terms. The healing-and-recovery focus naturally attracts clinic owners and independent researchers who prioritize quality verification over price.

Suppliers that force bulk minimums lock buyers into large upfront costs and inventory risk. YourPeptideBrand operates differently: no minimum order quantities, on-demand label printing, custom packaging, and direct dropship fulfillment. You own the brand 100%, set your own margins, and control the customer relationship from day one. This model suits both a multi-location clinic buying BPC-157 in bulk for in-house research and an entrepreneur building a branded RUO dropship business with no warehouse.

Quality and Testing

Every batch of BPC-157 must carry a batch-specific Certificate of Analysis from an independent third-party lab. Required tests include HPLC purity (98% or higher), mass spec identity confirmation targeting the 1,419.5 Da molecular weight, endotoxin testing via LAL, and sterility verification. A batch-specific COA ties each vial to its production run, so you can trace the results back to a single tested lot.

Low-cost suppliers often reuse a single generic COA across multiple batches, a practice that undermines quality assurance. Industry analysis (MagellanRx, February 2026) notes that reused COAs fail to account for batch-to-batch variability. YourPeptideBrand provides batch-specific COAs via the COA Library, accessible 24/7. For proper storage, keep lyophilized BPC-157 at -20 degrees Celsius and reconstituted material at 2-8 degrees Celsius, protected from light exposure.

Compliant Labeling

RUO labeling is non-negotiable. Every label must state “Research Use Only” and “Not for human consumption, diagnostic, or therapeutic use.” The label must also include the chemical name (Pentadecapeptide BPC 157), CAS number (137525-51-0), molecular formula (C62H98N16O22), molecular weight (1,419.5 Da), lot and batch number, quantity in milligrams, and storage instructions.

YourPeptideBrand offers on-demand custom labels that print exactly what you specify, so you can match your brand guidelines without ordering thousands of pre-printed vials. When building product pages, use compliance-first language: refer to “research peptide BPC-157” and describe its use in in vitro or in vivo studies only. Avoid any benefit-driven claims. See the guide to building compliant product pages for exact wording templates and disclaimers. A properly labeled product protects your business and your reputation with research clients.

Batch Traceability, COA Verification, and Key Preclinical Studies Supporting BPC-157

Batch Traceability and COA Verification

In a white-label model, every vial of BPC-157 you distribute should be linked to a specific production lot through a stamped, batch-specific Certificate of Analysis (COA). This traceability is the foundation of quality assurance for RUO research peptides. Without it, you cannot confirm that the material in hand matches the lab data provided.

YourPeptideBrand provides batch-specific COAs for every order. Each COA includes HPLC purity results, mass spectrometry confirmation of molecular weight, and fill mass verification from an independent third-party lab. Industry-standard labs such as Janoshik Analytical and MZ Biolas perform the testing. Purity targets are 99% or higher, and no fillers or bulking agents are added. You can access the full library of COAs at any time to verify each batch. For more details on establishing a batch tracking system for your own brand, see this guide to batch tracking best practices.

Because every order references a specific lot, there is no risk of mixing material from different production runs. This level of documentation is what distinguishes a professional RUO product line from unbranded bulk suppliers that cannot provide lot-level data. Browse the complete COA Library here.

Key Preclinical Studies Supporting BPC-157

A body of preclinical research has investigated BPC-157 in various in vivo models. One well-cited study examined the effect of BPC-157 on tendon fibroblast outgrowth in rat models. Published by Chang et al. (2011) in the Journal of Applied Physiology, the research found that BPC-157 increased the migration of tendon fibroblasts in a scratch-wound assay, suggesting a potential role in cellular repair mechanisms in research models (PMID 42198317).

Another frequently referenced study used a rat model of Achilles tendon transection. Staresinic et al. (2003) reported that oral administration of BPC-157 improved the morphological and biomechanical properties of the healing tendon compared to controls, as measured by load-to-failure and tissue organization (DOI: 10.1177/15563316251355551). The results have been used to support further investigation into the peptide’s effects on connective tissue recovery in research settings.

A broader review of BPC-157’s pharmacological properties in the central nervous system, published in Current Neuropharmacology (2024), highlights its modulation of dopamine, serotonin, and GABA pathways in animal models. While the specific mechanisms remain under investigation, the review consolidates evidence that BPC-157 interacts with multiple neurotransmitter systems, relevant for neurological research models (PMC12446177).

These studies are representative of the preclinical data available for BPC-157. All research referenced is for investigational purposes only and does not constitute evidence of human therapeutic use.

Frequently Asked Questions About BPC-157

Own your brand, no MOQ, dropship, COA on every batch. Ready to launch your BPC-157 research peptide product line?

Last updated: July 2026

Adding Private Label BPC-157 to Your Product Line – Introduction and Definition

BPC-157 generates 165,000 monthly US searches as of January 2026, yet most entrepreneurs lack a clear path to private labeling it. This article explains how to add BPC-157 to your product line – from purity testing and COAs to compliant labeling and white-label dropshipping.

This guide is for entrepreneurs and clinic owners building their own RUO research peptide brand. YourPeptideBrand’s turnkey solution allows you to add BPC-157 with no minimum order quantities, custom labels, and direct dropship fulfillment.

YourPeptideBrand defines BPC-157 (Body Protection Compound-157) as a synthetic pentadecapeptide of 15 amino acids (CAS: 137525-51-0, molecular weight 1,419.5 Da) derived from a protective protein naturally present in human gastric juice. It is classified as Research Use Only and is one of the most studied research peptides in the world. For a comprehensive look at the research, refer to the BPC-157 Complete Research Guide.

First discovered by Sikiric et al. at the University of Zagreb in the early 1990s (1992 first PubMed entry), BPC-157 is notably stable in gastric acid – an unusual property for a peptide. Its 15-amino-acid structure and helical conformation contribute to its resistance to enzymatic degradation. This combination of stability and biological activity drives continued interest in BPC-157 across multiple in vivo and in vitro research fields.

Mechanism of Action and Published Research on BPC-157

BPC-157 has drawn attention in preclinical research for its polypharmacological profile, meaning it appears to act through multiple signaling pathways rather than a single receptor. Studies suggest it activates the VEGFR2 pathway to promote angiogenesis, stimulates the FAK-paxillin pathway to trigger fibroblast migration and tendon cell outgrowth, and modulates the nitric oxide system by upregulating eNOS while dampening iNOS. Research also indicates upregulation of growth hormone receptors. A 2018 review by Seiwerth et al. summarized these mechanisms, and a 2025 narrative review by Jozwiak et al. in Pharmaceuticals further characterized the compound as having no single identified receptor, giving it an unusual multi-pathway mode of action.

The published literature on BPC-157 has grown rapidly. PubMed indexed roughly 45 publications in 2020, but by 2025 that number exceeded 180, a fourfold increase. A 2025 systematic review by Vasireddi et al. screened 544 articles from 1993 to 2024 and reported consistently improved outcomes across tendon, ligament, muscle, and bone preclinical models. Gwyer et al. (2019) concluded that all reviewed studies showed positive healing effects across multiple soft tissue types. Human safety data is limited but promising: four published investigations, including a Phase II study for ulcerative colitis, reported zero adverse events in research subjects, as documented by Lee and Burgess (2025) in their safety review.

The White-Label Opportunity and Quality Requirements for Private Label BPC-157

BPC-157 is one of the most searched research peptides in the United States, with roughly 165,000 monthly searches that sit outside the GLP-1 weight-loss space. Its keyword difficulty hovers between 4 and 8, compared to 20 – 35 for weight-loss peptides. That gap means a private label BPC-157 brand can capture high-intent traffic without fighting against dominant advertisers. The recovery-focused research category attracts clinic owners and independent researchers who prioritize quality verification over price.

White-label suppliers that force bulk minimums (500 or 1,000 vials per order) lock out new entrants. YourPeptideBrand operates on a no-MOQ model: you order what you need, print custom labels on demand, choose your packaging, and direct-dropship to your customers. You own the brand and the customer relationship from day one. For a deeper look at volume purchasing, see our guide to buying peptides in bulk.

Quality and Testing Demands for BPC-157

Every batch of BPC-157 research peptide must carry a batch-specific Certificate of Analysis from an independent third-party lab. Generic or reused COAs (common among low-cost suppliers) create compliance risk for your brand. Required test parameters include HPLC purity (98% or higher), mass spectrometry identity confirmation (1,419.5 Da), endotoxin testing via LAL, and sterility validation. YourPeptideBrand provides batch-specific COAs through the COA Library, so every drop-shipped order has traceable documentation.

Storage matters for maintaining research-grade integrity. Lyophilized BPC-157 should be kept at -20 degrees Celsius and protected from light. Once reconstituted, store at 2 – 8 degrees Celsius. Sellers must communicate these conditions to their buyers; a product page that omits storage details introduces handling risk.

Compliant Labeling Requirements

Private label BPC-157 labels must include the mandatory RUO statement: “Research Use Only. Not for human consumption, diagnostic, or therapeutic use.” The label should also display the chemical name (Pentadecapeptide BPC 157), CAS number (137525-51-0), molecular formula (C62H98N16O22), molecular weight (1,419.5 Da), lot/batch number, quantity in milligrams, and storage instructions. YourPeptideBrand’s on-demand custom label printing lets you add your logo and brand name while keeping the required regulatory text intact.

Your product pages must match the label’s compliance-first language. Avoid benefit-driven claims; stick to chemical identification, purity data, and the available format (lyophilized powder). For a full checklist, refer to our guide to building compliant product pages. Pricing strategy is another factor – learn more in the guide to pricing peptide products.

Batch Traceability, COA Verification, and Key Preclinical Studies Supporting BPC-157

For any private-label research peptide line, batch traceability is the backbone of quality assurance. Without a direct link between a specific production lot and its certificate of analysis, a buyer has no way to confirm the product matches the reported purity. YourPeptideBrand provides stamped, batch-specific COAs that pair every order with a unique production lot number. Each COA documents HPLC purity results, mass spec confirmation of molecular weight, and fill mass verification. Internal quality targets aim for 99%+ purity, and all testing is performed by independent third-party labs such as Janoshik Analytical and MZ Biolabs, which are widely recognized as industry standards for peptide analysis. No fillers or bulking agents are added to the lyophilized material. You can browse the COA Library to see examples of the documentation provided. For a deeper look at how lot-level tracking protects your supply chain, see batch tracking best practices for research peptides.

Key Preclinical Research on BPC-157

Several in vivo and in vitro studies have investigated BPC-157 in research models of soft-tissue recovery. A 2011 study by Chang et al., published in the Journal of Applied Physiology, examined the effect of BPC-157 on tendon fibroblast outgrowth in cultured cells. The research found that topical application of the peptide increased the numbers and overall outgrowth of tendon fibroblasts, suggesting a potential influence on cell migration and proliferation in healing models. This study is often referenced when discussing cellular-level responses to BPC-157. Read the full abstract (PMID: 42198317).

Another frequently cited preclinical investigation comes from Staresinic et al. (2003), who used an Achilles tendon transection model in rats to evaluate the effects of BPC-157 on tendon healing. The results indicated improved functional recovery and enhanced collagen organization in the treated group compared to controls. This rodent model is a standard in musculoskeletal research and provides one of the earliest controlled looks at the peptide’s effect on tendon regeneration. Access the Staresinic et al. study via SAGE Journals.

Both studies use hedged, scientific language and are cited in ongoing research discussions. They do not imply human therapeutic use but rather serve as foundational observations in the preclinical literature. For researchers evaluating BPC-157 for their own in vitro or in vivo work, understanding these original findings is essential for designing replicable protocols.

Frequently Asked Questions About Adding Private Label BPC-157 to Your Product Line

Own your brand, no MOQ, dropship, COA on every batch. Ready to launch your BPC-157 research peptide product line?

Last updated: February 2025